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The hyperplastic processes of the endometrium can arise not only against the background of excessive influence of estrogen, but 
also against the background of epigenetic damages that affect apoptosis, cell proliferation, differentiation, and adhesion, and DNA 
reparation. The aim of our study was to investigate and analyze the status of methylation of the promoter of SFRP2 gene in patients 
with hyperplastic processes of the endometrium. Materials and Methods: The study groups were the following: I — patients with 
endometrial hyperplasia (EH, n = 9); II — patients with endometrial intraepithelial neoplasia (EIN, n = 10), III — control groups: 
1) with endometrial cancer (EC, n = 4), and 2) healthy women (n = 4). Determination of promoter methylation of SFRP2 gene 
was carried out by the semiquantitative method of methylation-specific PCR assay. Results: The maximum level of methylation 
of SFRP2 gene promoter had been revealed in patients with EC — 42.80 ± 3.55% (р < 0.05). The patients of the I group had 
the lowest values of methylation of  SFRP2 gene promoter — 10.66 ± 0.85%, while in patients of the II group this indicator was 
higher — 20.60 ± 0.95% (р < 0.05). In healthy women of the control group, methylation of SFRP2 gene promoter was detected 
in none of the samples. Conclusion: The content of the methylated SFRP2 gene in endometrial tissue of patients with hyperplastic 
processes higher than 20–25% allows relate these women to the risk group of EC development and dictates the need of intensive 
observation of such patients.
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Hyperplastic processes of the endometrium (HPE) 
are related to the most actual problems in gynecology 
and require attention of obstetricians-gynecologists 
due to high risk of a malignization and recurrence [1, 
2]. HPE is considered to be the pathology of the en-
dometrium, which is characterized by diffuse or focal 
enlargement of the endometrium, and can arise not only 
at the background of excessive exposure to estrogen, 
but also via epigenetic disorders that affect apoptosis, 
inactivation of cell proliferation, differentiation, cell ad-
hesion, DNA repair and as a result, lead to an imbalance 
of proliferation and apoptosis [3–6].
Also the tendency of “rejuvenation” of this patho-
logy is supervised for last years. It is known, that endo-
metrial cancer (EC) develops against the background 
of an endometrial hyperplasia (EH) in about 50% 
of cases. Different morphological types of the HPE 
(from a simple EH without atypia to an EC) represent 
the progressing changes in histo- and cytoarchitecto-
nics with accumulation of the nosospecific molecular 
and genetic changes of cells [7, 8].
An abnormal methylation of DNA is the earliest 
event, which occurs in cell before the morphological 
manifestation of an EH. It is revealed that methylation 
of CpG-islands is the cause of loss of an expression 
of the corresponding genes due to the blocking of their 
transcription [7, 9]. Determination of the status of DNA 
methylation of nosospecific genes helps with early and 
differential diagnosis of tumors, and also is an impor-
tant event for observation and the prognosis.
The study [10] showed that methylat ion 
of FOXP3 gene promoter in patients with EC is around 
56–77%. Another study [11] showed that the de-
velopment of HPE is not associated with WIF1 gene 
methylation.
SFRPs family secreting proteins are antagonists 
of a Wnt-regulatory pathway, they suppress this signal-
ing pathway in healthy individuals. The Wnt-signaling 
pathway promotes the regulation of proliferation 
and differentiation of cells. It is proved that in some 
malignant tumors, such as a colorectal cancer, tu-
mors of head and neck, gastric cancer, methylation 
of genes-antagonists of a Wnt-signaling pathway is the 
reason of uncontrollable cellular proliferation [12, 13].
Traditionally, ultrasound, endoscopic and patho-
morphological methods of a research are used for 
diagnostics of HPE [14]. But none of these methods 
shows an exact assessment; even the discrepancy 
an atypical hyperplasia and EC in differential diagnos-
tics by morphologists constitutes 11–20% of cases [7]. 
There is a need for search of more reliable, early cri-
teria of HPE diagnostics by determination of a condi-
tion of DNA methylation. Therefore, research of the 
methylation status of SFRP2 gene in patients with HPE 
and patients with EC is actual for modern gynecologic 
practice.
The aim of our study was to investigate and 
analyze the DNA methylation status of the promoter 
of SFRP2 gene in patients with HPE.
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MATERIALS AND METHODS
27 (100%) patients at the age of 18–76 years, have 
participated in a research, criteria of inclusion were 
the following: the informed patient’s consent to par-
ticipation in a research; age — reproductive, peri- and 
postmenopausal; pathomorphologically confirmed 
diagnosis of HPE. Criteria of an exclusion were the 
age < 18 years or pregnancy.
Involved in the research patients were treated in the 
Gynecology Department of Multidisciplinary Medical 
Center University Clinic # 1 of Odesa National Medi-
cal University in a planned or urgent order and were 
operated thereon due to abnormal uterine bleeding, 
HPE. Diagnoses were confirmed by ultrasound dia-
gnostics before an operative intervention. Preoperative 
examination and preparation of patients were carried 
out by standard principles according to the order 
of Ministry of Health Care of Ukraine No. 620 from 
29.12.2003. The extent of an operative intervention 
was chosen individually for each patient. It depended 
on a clinical situation: a hysteroscopy with a biopsy 
of endometrium, curettage of a mucous cavity of the 
uterus, a hysterectomy with/without uterus appenda-
ges, pipelle biopsy of the endometrium. The existence 
of HPE was confirmed pathomorphologically in all pa-
tients who participated in a research according to EIN-
classification of HPE: EH, endometrial intraepithelial 
neoplasia (EIN) and classification of histopathologi-
cal subtypes of EC: endometrioid adenocarcinoma, 
mucinous carcinoma, serous carcinoma, clear cell 
carcinoma, squamous cell carcinoma, undifferentiated 
carcinoma, mixed carcinoma, metastatic carcinoma 
[1, 15–17].
Depending on the HPE morphological type, exam-
ined patients were distributed into the groups: I) EH — 
9 (33.3%) patients; II) EIN — 10 (37.1%) patients; 
III) control groups: 1) EC — 4 (14.8%) patients, and 
2) healthy women — 4 (14.8%).
The age of patients of the I group was 18–59 years, 
among them 6 (66.7%) patients were of reproductive 
age, 2 (22.2%) patients — of perimenopausal age, 
1 (11.1%) patient of postmenopausal age. 3 (33.3%) 
patients, mainly perimenopausal and postmeno-
pausal age, were observed by the therapist because 
of an idiopathic hypertension. 2 (22.2%) patients had 
high index of body weight — 29.2; 33.4. A hysteroscopy 
with a “cold” curettage of endometrium was carried out 
to 5 (55.6%) patients, indications to which were sterility 
in 2 (40.0%) cases and HPE according to an ultrasound 
examination in 3 (60.0%) cases. The hysteroscopy was 
carried out with the use of the endoscopic equipment 
Karl Storz (Germany). The fractional diagnostic curet-
tage of endometrium was carried out to 3 (33.3%) 
women, due to an abnormal uterine bleeding. 1 (11.1%) 
patient underwent a hysterectomy without appendages 
(basic disease is hysteromyoma with a hemorrhagic 
syndrome). USE of organs of the small pelvis, which 
was carried out by the device ALOKA Pro Sound SSD 
5000 (Japan), showed disharmony of thickness of en-
dometrium to a phase of a menstrual cycle, heteroge-
neity and hyperechogenicity of the endometrium. USE 
of organs of a small pelvis had shown the existence 
of non-uniform hyperechoic-thickened endometrium 
(11–19 mm — in reproductive age, 5–11 mm — in post-
menopausal period). Also it was established that 
1 (11.1%) patients had polycystic ovaries, 3 (33.3%) — 
hysteromyoma, 1 (11.1%) — adenomyosis.
The age of patients of the II group was 39–64 years: 
2 (20.0%) patients of reproductive age and 4 (40.0%) 
patients of perimenopausal and postmenopausal age. 
5 (50.0%) women had high index of body weight — 
28.3–37.4. 5 (50.0%) patients had normal weight. A half 
of patients were observed by the therapist because 
of a hypertension. 7 (70.0%) patients had appealed 
because of menstrual disorders, which turned into ab-
normal uterine bleeding. 3 (30.0%) patients with a dis-
ease of endometrium had no symptoms. USE of organs 
of a small pelvis had shown the existence of non-uniform 
hyperechoic thickened endometrium (14–23 mm in re-
productive age, 9–17 mm — in postmenopausal period). 
Also ultrasound revealed uterine myoma in 5 (50.0%) 
women and 1 (10.0%) patient — adenomyosis. 4 (40.0%) 
patients had an operative intervention — a hysterectomy 
with appendages, 2 (20.0%) women had a hysteroscopic 
resection of the endometrium, and 4 (40.0%) patients — 
the dilation and curettage of the uterus.
The age of patients of the control group with EC was 
49–72 years. 3 (75.0%) patients were at postmeno-
pause, 1 (25.0%) — of reproductive age. The index 
of body weight of patients with EC was more than 30, that 
confirmed an obesity; 2 (50.0%) patients were on the reg-
ular medical check-up at the therapist because of an id-
iopathic hypertension, 1 (25.0%) — under observation 
of the endocrinologist because of a II type diabetes mel-
litus. All patients with EC had complained on menstrual 
disorders in the form of a heavy irregular menses and ab-
normal uterine bleedings. 2 (50.0%) patients underwent 
the uterus curettage, 2 (50.0%) patients — a hystero-
scopy for biopsy of endometrium. According to results 
of USE of organs of the small pelvis, which were carried 
out before an operative intervention, all 4 (100%) patients 
had the enlargement of the endometrium (in reproduc-
tive age — 18–28 mm, 11–24 mm — at postmenopausal 
period), its heterogeneity, in equality of an external con-
tour, absence of accurate margins between the tumor 
center and a myometrium. The hysteromyoma had been 
diagnosed in 2 (50.0%) patients, and adenomyosis had 
been diagnosed in 1 (25.0%) patient.
The healthy women of the control group (4 (100.0%)) 
without pathology of the endometrium participated 
in the study and were examined in the clinic for prepara-
tion to the in vitro fertilization program because of male 
infertility factor. The age of the examined control group 
was 29–36 years. The absence of the pathology of the 
endometrium is confirmed morphologically (pipelle 
biopsy of the endometrium) and by ultrasound of the 
pelvic organs (M-echo 5–13 mm). Genital and extra-
genital pathology in the control group women were not 
detected.
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Determination of methylation of the DNA promoter 
of SFRP2 gene was carried out by the semiquantitative 
method of methylation-specific PCR assay.
DNA from samples of endometrium tissues were 
isolated with use of DNeasy Blood & Tissue Kit (Qiagen, 
USA). Bisulfite processing of DNA was carried out with 
using EpiTect Bisulfite Kit (Qiagen, USA) according 
to the protocol of the manufacturer. The amount of DNA 
for bisulfite processing of DNA in all tests was 1 µg/ml. 
Amplification of DNA after bisulfite processing was car-
ried out using Hot Start DNA Polymerase Kit according 
to the program 95 °C — 15 min; 95 °C — 30 s, 50 °C — for 
a unmethylated DNA and 56 °C — for the methylated 
DNA, 72 °C — 30 s, 39 cycles; 72 °C — 10 min (Table 1).
Table 1. The sequence of primers for amplification of the methylation- specific 
site of SFRP2 promoter
Type Sequence of primers t, °С
For methylated 
SFRP2 gene
F_M_GGGTCGGAGTTTTTCGGAGTTGCGC
R_M_CCGCTCTCTTCGCTAAATACGACTCG
56
For unmethylated 
SFRP2 gene
F_U_TTTGGGTTGGAGTTTTTTGGAGTTGTGT
R_U_AACCCACTCTCTTCACTAAATACAACTCA
50
The PCR products were examined using 2% 
agarose gel electrophoresis, stained with ethidium 
bromide. The relative content the methylated and 
unmethylated DNA was assessed using the Quantity 
One 1D Analysis Software program (BIO-RAD, USA) 
on the device Versa Doc МР 4000 System (BIO-RAD, 
USA) according to the formula: 
M (%) = A • 100 / (A + B), 
where A — is the area of peak of methylated DNA, B — 
is the area of peak of unmethylated DNA, M — relative 
content the methylated DNA.
The molecular-biological studies of the DNA 
methylation were controled by EpiTech Control DNA 
unmethylated (Qiagen, USA) and EpiTect Control DNA 
methylated (Qiagen, USA).
Statistical analysis of the data obtained was 
validated using MedCalc 14.8.1 and Microsoft Excel 
2010 packages with the AtteStat add-in 12.5. The 
average sample values of the quantitative attributes 
are given as M ± m, where M is the mean selective, 
m is the mean error. Taking into account the small 
number of observations in the groups for comparison 
of the main parameters, nonparametric methods were 
used — the medication test of Kruskal — Wallis, the 
Mann — Whitney test and the Wald — Wolfowitz series.
RESULTS AND DISCUSSION
The analysis of the obtained data on methylation 
of the promoter of SFRP2 gene has revealed significant 
differences between the patients with EH, EIN, EC and 
healthy women (Table 2, Fig. 1, 2).
Table 2. The content of methylated DNA of a gene SFRP2 in the studied 
samples of endometrium
Case Morphological type of the endometrium
The content of SFRP2 gene 
methylation, %
1 EH 8
2 EH 12
3 EH 16
4 EH 9
5 EH 11
6 EH 11
7 EH 12
8 EH 8
9 EH 9
10 EIN 22
11 EIN 17
12 EIN 17
13 EIN 19
14 EIN 24
15 EIN 26
16 EIN 23
17 EIN 19
18 EIN 20
19 EIN 19
20 EC 33
21 EC 45
22 EC 49
23 EC 51
24 PE 0
25 PE 0
26 PE 0
27 SE 0
Notе: PE — proliferative endometrium; SE — secretory endometrium.
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Fig. 1. The level of methylated SFRP2 gene in the studied endometrial samples. Cases 1–9 — patients with EH, 10–19 — patients 
with EIN, 20–23 — patients with EC, 24–27 — healthy women
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The maximum level of methylation of the stud-
ied gene had been found in patients with EC — 
42.80 ± 3.55% (р < 0.05), that is nearly by 4-fold 
higher, than in patients with EH and by 2-fold than 
in patients with EIN. It was revealed that patients 
with EH had the lowest values of this index; the av-
erage content of the methylated SFRP2 gene was 
10.66 ± 0.85%, while in patients with EIN this index 
was 20.60 ± 0.95% (р < 0.05) (Fig. 1, 2, Table 2). 
In healthy women of the control group, methylation 
of the investigated gene was detected in none of the 
cases, therefore, the graphic representation of the 
results was not performed (Table 2).
It is necessary to note that methylation of the pro-
moter of SFRP2 gene didn’t depend on the age of the 
patients, existence of the accompanying gynecologic 
pathology (hysteromyoma, adenomyosis, polycystic 
ovaries).
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Fig. 2. Methylation of the promoter of SFRP2 gene in patients 
with EH, EIN and EC
Also, an assessment of the intensity of methylation 
of the promoter of SFRP2 gene confirmed the results 
(Fig. 3) shown above. The methylation of DNA in con-
trol sample (№ 1) was taken as 50%. In comparison 
with the control, the minimum intensity of methylation 
was noted in patients with EH (samples № 3, № 4, 
№ 5). The maximal intensity of DNA methylation was 
found in patients with EC (samples № 6, № 7), being 
higher in comparison with patients with EH (№ 3, № 4, 
№ 5) and the EIN (№ 2).
Fig. 3. Intensity of methylation of the promoter of SFRP2 gene 
in endometrial samples from different groups under study. M — 
methylated DNA; U — unmethylated DNA
The dependence between the level of DNA methy-
lation and a morphological stage of HPE has shown 
its lowest level in patients with EH, and the highest — 
in patients with EC. Average values of DNA methylation 
were characteristic for patients with EIN.
The data on the status of SFRP2 methylation 
in patients with HPE and EC in the literature are 
scarce. In the paper of Di Domenico et al. [18] in has 
been shown that methylation of SFRP2 gene could 
not serve as a diagnostic criterion for the diagnosis 
of EC, as it was detected in 2 out of 39 examined 
patients with HPE and EC. There is a high incidence 
of methylation of another gene from the Secreted 
Frizzled Related Protein family, SFRP1, among the 
EC specimens and this index allow clearly distinguish 
benign and malignant areas of the mucosal tissue 
of the uterine cavity. The results of our study showed 
a high frequency of SFRP2 gene methylation among 
patients with HPE, with a direct relationship between 
the degree of methy lation and the morphological type 
of the endometrium pathology: EH → EIN → EC. There 
are some data that the state of SFRP2 gene methyla-
tion could also be used to diagnosis of oncological 
processes of other localizations (colorectal, ovarian, 
lung cancer), not only EC [19–21].
CONCLUSION
Thus, the presence of not only morphological 
changes in case of HPE, but also characteristic 
changes of SFRP2 methylation in different types 
of HPE, expands diagnostic criteria of this nosology. 
Low content of the methylated DNA (10.66 ± 0.85%) 
in case of EH and high content of the methylated 
DNA (42.80 ± 3.55%) in patients with EC, allow to use 
determination of relative content of the methylated 
SFRP2 gene as a marker of differential diagnostics 
of HPE and early prognosis of risk of its maligniza-
tion. The SFRP2 gene can be used as a marker for 
the differential diagnosis of HPE and EC. The content 
of the methylated SFRP2 gene in endometrial tissue 
of patients with hyperplastic processes higher than 
20–25% allows relate these women to the risk group 
of EC development and dictates the need of intensive 
observation of such patients.
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